




# PHARMACEUTICAL 2021

Avalo Therapeutics Inc.  
Rank 324 of 402





# PHARMACEUTICAL 2021

Avalo Therapeutics Inc.  
Rank 324 of 402



The relative strengths and weaknesses of Avalo Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Avalo Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 88% points. The greatest weakness of Avalo Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 128% points.

The company's Economic Capital Ratio, given in the ranking table, is -68%, being 115% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	26,005
Cost of Goods Sold	300
Intangible Assets	15,994
Liabilities, Current	15,225
Liabilities, Non-Current	1,878
Other Assets	1,756
Other Compr. Net Income	0
Other Expenses	26,839
Other Liabilities	2,090
Other Net Income	6,550
Other Revenues	6,699
Property and Equipment	0
Research and Development	32,192
Selling, General and Administrative Expense	17,417

Output Variable	Value in 1000 USD
Assets	43,755
Liabilities	19,194
Expenses	76,749
Revenues	6,699
Stockholders Equity	24,562
Net Income	-63,500
Comprehensive Net Income	-63,500
Economic Capital Ratio	-68%